Partners
BIOPRAXIS Research was constituted in 2006 with the aim of gathering the R&D activities in new medicines of the pharmaceutical Praxis Group, established in Vitoria (Spain).
The company is mainly devoted to the R&D activities in the field of APIs (Active Pharmaceutical Ingredients) obtained from biotechnology and biochemistry processes.One of its main strategic lines is focused on regenerative medicine for the treatment of chronic wounds.
BIOPRAXIS is highly active in R&D for the development of novel therapeutic alternatives for rare diseases, mainly Lysosomal storage diseases and Cystic Fibrosis, using nanotechnology and biological molecules like proteins, enzymes and peptides.
This profile perfectly suits with Smart4Fabry proposal, in which Biopraxis will be in charge of the translation of the existent formulation prototypes to pilot industrial scale.
Biopraxis will lead the transference of the optimized GLA nanoformulation from the laboratory level to a pilot industrial scale designed and operated under GMP conditions. Biopraxis will play also a relevant role in the design of the exploitation and business development strategy for the project outcomes.
Biopraxis has wide experience in the development of collaborative projects at the EU level for translation of nanomedicines to pilot scale production and design of adequate strategies for exploitation. Biopraxis holds the Chairmainship of the Working group Nanotherapeutics at ETPN, and will use this position to attract stakeholders for the Smart4Fabry Project.
Biopraxis will lead the transference of the optimized GLA nanoformulation from the laboratory level to a pilot industrial scale designed and operated under GMP conditions. Biopraxis will play also a relevant role in the design of the exploitation and business development strategy for the project outcomes.